#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "choi2014"
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Rana Aldisi"
SET DOCUMENT Description = "This file encodes the article Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia by Choi et al, 2014"

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns"
DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns"
DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns"
# DEFINE NAMESPACE FB           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/80171ae62cf43aa1fc8a6c326b94537ab342458c/external/fb-names.belns"
DEFINE NAMESPACE HBP            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/7e4be528f12abd28be768b62402fba6e083eaf9e/export/hbp-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns"
DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns"
DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns"
DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns"
DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/mesh-names.belns"
DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns"
DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns"
DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns"
DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns"
DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns"

# Namespaces hosted on https://arty.scai.fraunhofer.de/artifactory/bel/namespace
# ------------------------------------------------------------------------------
DEFINE NAMESPACE CTO            AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns"
DEFINE NAMESPACE DO             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns"
DEFINE NAMESPACE HP             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns"
DEFINE NAMESPACE SCOMP          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns"
DEFINE NAMESPACE SFAM           AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############
SET Citation = {"PubMed", "24511233"}

SET Evidence="Schizophrenia (SZ) and Alzheimer’s disease (AD) are two devastating disorders of the
central nervous system (CNS) that present clinically with cognitive impairments and
psychotic symptoms"

SET MeSHAnatomy="Central Nervous System"

path(MESH:"Alzheimer Disease") -- path(MESH:"Psychotic Disorders")
path(MESH:"Alzheimer Disease") -- path(MESH:"Cognitive Dysfunction")
path(MESH:Schizophrenia) -- path(MESH:"Psychotic Disorders")
path(MESH:Schizophrenia) -- path(MESH:"Cognitive Dysfunction")

UNSET MeSHAnatomy

SET Evidence="Psychosis is the hallmark symptom of SZ and manifests as hallucinations,
disordered thought/speech, and delusions. While these psychotic symptoms are
commonly associated with SZ, it has become well documented that these patients also
experience cognitive and behavioral disturbances that are not adequately addressed by
currently prescribed typical and atypical psychotics."

path(MESH:Schizophrenia) -- path(MESH:Hallucinations)
path(MESH:Schizophrenia) -- path(MESH:Delusions)
path(MESH:Schizophrenia) -- bp(GO:cognition)
path(MESH:Schizophrenia) -- bp(GO:behavior)

SET Evidence="Conversely, the most commonly
associated symptoms of AD are cognitive in nature and include deficits in learning
and memory. However, 50%–80% of AD patients display psychotic and behavioral
disturbances that are correlated with poor social and functional outcomes"

path(MESH:"Alzheimer Disease") -- bp(GO:cognition)
path(MESH:"Alzheimer Disease") -- bp(GO:learning)
path(MESH:"Alzheimer Disease") -- bp(GO:memory)
path(MESH:"Alzheimer Disease") -- path(MESH:"Psychotic Disorders")

SET Evidence="Another commonality between AD and SZ is the apparent
involvement of dysregulated cholinergic signaling in
the brain."

path(MESH:"Alzheimer Disease") -| bp(GO:"synaptic transmission, cholinergic")
path(MESH:Schizophrenia) -| bp(GO:"synaptic transmission, cholinergic")

SET Evidence="Acetylcholine (ACh) is a neurotransmitter that
modulates neuronal function in several areas of the CNS
associated with AD and/or SZ pathology, including the
striatum, cortex, hippocampus, and prefrontal cortex.5
 ACh mediates its actions via two families of receptors, termed
the muscarinic ACh receptors (mAChRs) and the nicotinic
ACh receptors (nAChRs)."

SET MeSHAnatomy={"Corpus Striatum", "Cerebral Cortex", "Hippocampus", "Prefrontal Cortex"}

a(CHEBI:acetylcholine) reg act(a(MESH:Neurons))
p(HGNCGENEFAMILY:"Cholinergic receptors muscarinic") reg act(a(CHEBI:acetylcholine))
p(HGNCGENEFAMILY:"Cholinergic receptors nicotinic subunits") reg act(a(CHEBI:acetylcholine))

UNSET MeSHAnatomy

SET Evidence="The mAChR family consists of five subtypes (M1
–M5) that can be found throughout the CNS and periphery.
These receptors are guanosine nucleotide-binding protein
(G-protein)-coupled receptors and can be subdivided based
on their canonical signaling pathways."

p(HGNCGENEFAMILY:"Cholinergic receptors muscarinic") hasMembers list(p(HGNC:CHRM1), p(HGNC:CHRM2), p(HGNC:CHRM3), p(HGNC:CHRM4), p(HGNC:CHRM5))
p(HGNCGENEFAMILY:"Cholinergic receptors muscarinic") isA p(MESH:"Receptors, G-Protein-Coupled")

SET Evidence="M1, M3, and M5 all
signal primarily via the Galphaq G-protein and induce Ca2+ mobilization
and inositol trisphosphate (IP3) production, while M2
and M4 signal via the Galphai G-protein to inhibit cyclic adenosine
monophosphate (cAMP) production."

complex(p(HGNC:CHRM1), p(HGNC:GNAQ)) -> bp(GO:"calcium ion transport")
complex(p(HGNC:CHRM1), p(HGNC:GNAQ)) -> a(MESH:"Inositol 1,4,5-Trisphosphate")
complex(p(HGNC:CHRM3), p(HGNC:GNAQ)) -> bp(GO:"calcium ion transport")
complex(p(HGNC:CHRM3), p(HGNC:GNAQ)) -> a(MESH:"Inositol 1,4,5-Trisphosphate")
complex(p(HGNC:CHRM5), p(HGNC:GNAQ)) -> bp(GO:"calcium ion transport")
complex(p(HGNC:CHRM5), p(HGNC:GNAQ)) -> a(MESH:"Inositol 1,4,5-Trisphosphate")
complex(p(HGNC:CHRM2), p(HGNC:GNAI1)) -| a(CHEBI:"3',5'-cyclic AMP")
complex(p(HGNC:CHRM4), p(HGNC:GNAI1)) -| a(CHEBI:"3',5'-cyclic AMP")


SET Evidence="AD is the most commonly diagnosed form of dementia
and currently affects approximately 35 million individuals
worldwide.7 AD is a progressive neurodegenerative disease
that is characterized by a host of cognitive deficits, including
impairments in learning and memory. In addition to the
well-documented cognitive impairments, AD patients also
display behavioral disturbances, including anxiety, depression,
and psychosis"

path(MESH:"Alzheimer Disease") -- path(MESH:Dementia)
path(MESH:"Alzheimer Disease") isA path(MESH:"Neurodegenerative Diseases")
path(MESH:"Alzheimer Disease") -- path(MESH:"Cognitive Dysfunction")
path(MESH:"Alzheimer Disease") -| bp(GO:cognition)
path(MESH:"Alzheimer Disease") -| bp(GO:learning)
path(MESH:"Alzheimer Disease") -> path(MESH:Depression)
path(MESH:"Alzheimer Disease") -> path(MESH:Anxiety)
path(MESH:"Alzheimer Disease") -- path(MESH:"Psychotic Disorders")

SET Evidence="Age is the primary risk factor for AD,
and the disease usually manifests in individuals after the age
of 60 years. Due to an aging population, the prevalence of AD
is predicted to rise to 66 million people by the year 2030."

path(MESH:"Alzheimer Disease") -- bp(MESH:Aging)

SET Evidence="The hallmarks of AD pathology are the accumulation of
amyloid-beta (Abeta) peptide aggregates (neuritic plaques) and
hyperphosphorylated tau protein (neurofibrillary tangles)."

a(HBP:"amyloid-beta aggregates") -- path(MESH:"Plaque, Amyloid")
path(MESH:"Plaque, Amyloid") biomarkerFor path(MESH:"Alzheimer Disease")
path(MESH:"Neurofibrillary Tangles") biomarkerFor path(MESH:"Alzheimer Disease")

SET Evidence="The popular amyloid cascade hypothesis posits that the
gradual build-up of Abeta plaques leads to neuronal inflammation,
dysfunction, and, eventually, cell death. The two
brain regions most critically affected by this degeneration
are the cortex and hippocampus, both of which are involved
in cognition, learning, and memory."

SET MeSHAnatomy={"Hippocampus", "Cerebral Cortex"}

path(MESH:"Plaque, Amyloid") -> bp(HBP:neuroinflammation)
path(MESH:"Plaque, Amyloid") -> bp(GO:"cell death")
a(MESH:Hippocampus) -- bp(GO:cognition)
a(MESH:Hippocampus) -- bp(GO:learning)
a(MESH:Hippocampus) -- bp(GO:memory)
a(MESH:"Cerebral Cortex") -- bp(GO:cognition)
a(MESH:"Cerebral Cortex") -- bp(GO:learning)
a(MESH:"Cerebral Cortex") -- bp(GO:memory)

UNSET MeSHAnatomy

SET Evidence="1 Several lines of evidence
suggest that impaired cholinergic signaling plays a
key role in mediating both the cognitive and the behavioral
impairments observed in AD patients.12 The basal forebrain
cholinergic system is disproportionately affected in AD
patients, with a robust loss of cholinergic neurons, including
those innervating the hippocampus and cortex."

path(MESH:"Alzheimer Disease") -| bp(GO:"synaptic transmission, cholinergic")
bp(GO:"synaptic transmission, cholinergic") -- bp(GO:cognition)
bp(GO:"synaptic transmission, cholinergic") -- bp(GO:behavior)

SET MeSHAnatomy={"Hippocampus", "Cerebral Cortex"}

path(MESH:"Alzheimer Disease") -| a(MESH:"Cholinergic Neurons")

UNSET MeSHAnatomy

SET Evidence=" In addition,
administration of nonselective muscarinic antagonists
can produce or exacerbate cognitive deficits in animals,15
as well as in AD patients and both young and old control
subjects,16,17 suggesting that mAChRs can directly modulate
cognition."

SET MeSHDisease="Alzheimer Disease"

a(MESH:"Muscarinic Antagonists") -| bp(GO:cognition)
p(HGNCGENEFAMILY:"Cholinergic receptors muscarinic") reg bp(GO:cognition)

UNSET MeSHDisease

SET Evidence="The current primary treatments for AD symptoms
are acetylcholinesterase inhibitors (AChEIs) such as donepezil,
tacrine, galantamine, and rivastigmine, which potentiate
cholinergic signaling.18,19 These treatments not only provide
improvements in cognitive symptoms associated with
AD,20,21 but also show efficacy in treating the psychiatric
symptoms."

SET MeSHDisease="Alzheimer Disease"

a(CHEBI:donepezil) isA a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor")
a(CHEBI:tacrine) isA a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor")
a(CHEBI:galanthamine) isA a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor")
a(CHEBI:rivastigmine) isA a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor")
a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") -> bp(GO:"synaptic transmission, cholinergic")
a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") -> bp(GO:cognition)
a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") -> path(MESH:"Mental Processes")

UNSET MeSHDisease

SET Evidence="Unfortunately, cardiovascular and gastrointestinal
side effects are often observed with these treatments,
effects thought to be mediated by peripherally located ACh
receptors. Despite this, AChEIs remain modestly beneficial
for treating AD and other forms of dementia."

a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") -- a(MESH:"Cardiovascular System")
a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") -- a(MESH:"Gastrointestinal Tract")

SET Evidence="The hallmark psychotic
symptoms of SZ are the positive cluster and include auditory
hallucinations, delusional beliefs, and disorganized thoughts
and speech. SZ patients also exhibit negative symptoms,
including anhedonia, dysfunctional social interactions, and
poverty of thoughts and speech, as well as cognitive disturbances
affecting several behavioral domains, including working
memory, attention, and executive function"

path(MESH:Hallucinations) biomarkerFor path(MESH:Schizophrenia)
path(MESH:Delusions) biomarkerFor path(MESH:Schizophrenia)
path(MESH:Anhedonia) biomarkerFor path(MESH:Schizophrenia)
path(MESH:"Social Isolation") biomarkerFor path(MESH:Schizophrenia)
path(MESH:"Memory, Short-Term") -- path(MESH:Schizophrenia)
path(MESH:Attention) -- path(MESH:Schizophrenia)
path(MESH:"Executive Function") -- path(MESH:Schizophrenia)

SET Evidence="Current treatments include both typical (eg, haloperidol and
chlorpromazine) and atypical (eg, risperidone and clozapine)
antipsychotics, which act on the dopaminergic system and D2
dopamine receptors in particular. These treatments show
partial efficacy in reducing psychotic or positive symptoms;30
however, they demonstrate little to no efficacy in addressing
negative symptoms and cognitive impairments, which can
prevent patients from participating fully and productively in
society"

a(CHEBI:"antipsychotic agent") reg p(HGNC:DRD2)
a(CHEBI:"antipsychotic agent") causesNoChange bp(GO:cognition)

SET Evidence="Accumulating evidence suggests that the three clusters of
SZ symptoms cannot be ascribed solely to alterations in
monoaminergic signaling as dysregulation of glutamatergic,
gamma-aminobutyric acid (GABA)-ergic, and cholinergic systems
have also been reported"

path(MESH:Schizophrenia) -- bp(GO:"synaptic transmission, cholinergic")
path(MESH:Schizophrenia) -- bp(GO:"synaptic transmission, glutamatergic")
path(MESH:Schizophrenia) -- bp(GO:"gamma-aminobutyric acid signaling pathway")

SET Evidence="Furthermore, administration of nonselective muscarinic
antagonists can induce cognitive deficits and psychosis in
humans,16,37 indicating that mAChR activation may provide
pro-cognitive and antipsychotic efficacy."

a(MESH:"Muscarinic Antagonists") -> path(MESH:"Cognitive Dysfunction")
a(MESH:"Muscarinic Antagonists") -- path(MESH:"Mental Processes")

SET Evidence="Of these, the M1/M4
-preferring agonist xanomeline was the
only one to progress to a phase III clinical trial, where it
was assessed for efficacy in ameliorating cognitive deficits
observed in AD patients. While xanomeline showed a trend
toward improving cognitive function in these patients, this
effect did not reach statistical significance. However, this
agonist did produce surprisingly robust and dose-dependent
reductions in hallucinations, delusions, vocal outbursts,
and other behavioral disturbances in these patients"

SET MeSHDisease="Alzheimer Disease"

a(CHEBI:xanomeline) -> bp(GO:cognition)
a(CHEBI:xanomeline) -| path(MESH:Hallucinations)
a(CHEBI:xanomeline) -| path(MESH:Delusions)

UNSET MeSHDisease

SET Evidence="This study reported that xanomeline treatment produced
robust improvements in both the positive and the negative
symptoms of patients with SZ"

a(CHEBI:xanomeline) -| path(MESH:Schizophrenia)

SET Evidence=" In addition, xanomeline produced statistically
significant improvements in verbal learning and short-term
memory, indicating efficacy in treating cognitive symptoms.40
Unfortunately, gastrointestinal side effects were observed,
and dose limitations have removed it from consideration for
long-term clinical use."

a(CHEBI:xanomeline) -> bp(GO:learning)
a(CHEBI:xanomeline) -> path(MESH:"Memory, Short-Term")
a(CHEBI:xanomeline) -- a(MESH:"Gastrointestinal Tract")

SET Evidence="The M1 mAChR subtype is the most predominantly expressed mAChR
subtype in the CNS and is expressed in several brain regions implicated in
the regulation of cognitive processes, including the striatum, prefrontal
cortex, and hippocampus."

SET MeSHAnatomy={"Corpus Striatum", "Hippocampus", "Prefrontal Cortex"}

p(HGNC:CHRM1) -- bp(GO:cognition)

UNSET MeSHAnatomy

SET Evidence="Interestingly, these M1-deficient mice display increased
amphetamine-induced hyperlocomotion and dopamine neurotransmission,47
indicating that M1 modulation may have antipsychotic potential."

p(HGNC:CHRM1) -| act(a(CHEBI:amphetamine))
p(HGNC:CHRM1) -| bp(GO:"dopamine secretion, neurotransmission")

SET Evidence="N-methyl-D-aspartate (NMDA)
receptors play a critical role in regulating synaptic plasticity, and
disrupted NMDA-receptor neurotransmission is thought to underlie the
cognitive deficits observed in numerous psychiatric diseases."

p(HGNCGENEFAMILY:"Glutamate ionotropic receptor NMDA type subunits") reg bp(MESH:"Neuronal Plasticity")
p(HGNCGENEFAMILY:"Glutamate ionotropic receptor NMDA type subunits") -- bp(GO:cognition)

SET Evidence="M1 mAChRs have been demonstrated to potentiate NMDA-receptor
signaling in the hippocampus and cortex,48,49 brain areas intimately
associated with learning and memory. In addition, M1 KO mice displayed
reduced hippocampal long-term potentiation, a mechanism heavily implicated
in learning and memory. Behaviorally, M1 KO animals display deficits in several
medial prefrontal cortex-dependent cognitive tasks, including non-matching-to-
sample, win-shift radial arm maze, and social discrimination tasks."

SET MeSHAnatomy={"Hippocampus", "Cerebral Cortex"}

p(HGNC:CHRM1) -> act(p(HGNCGENEFAMILY:"Glutamate ionotropic receptor NMDA type subunits"))
a(MESH:Hippocampus) -- bp(GO:learning)
a(MESH:Hippocampus) -- bp(GO:memory)
a(MESH:"Cerebral Cortex") -- bp(GO:learning)
a(MESH:"Cerebral Cortex") -- bp(GO:memory)
p(HGNC:CHRM1) -> bp(GO:"long-term synaptic potentiation")
bp(GO:"long-term synaptic potentiation") -- bp(GO:learning)
bp(GO:"long-term synaptic potentiation") -- bp(GO:memory)

UNSET MeSHAnatomy

SET Evidence="Finally, studies in mice exhibiting AD-like Abeta plaque
pathologies found that deletion of M1 increased amyloidogenic processes,
suggesting that M1 may play a role in regulating AD disease progression.51"

SET Species="10090"
SET MeSHDisease="Alzheimer Disease"

p(MGI:Chrm1) -| act(a(CHEBI:"amyloid-beta"))

UNSET Species
UNSET MeSHDisease

SET Evidence="Subsequent optimization produced two analogs of AC-42
(AC-260584 and 77-LH-28-1), which maintained M1 selectivity and possessed
properties suitable for use in animal models. Both AC-260584 and 77-LH-28-1
displayed antipsychotic and cognition-enhancing efficacy in pre-clinical models"

#AC-260584 = 4-(3-(4-butylpiperidin-1-yl)propyl)-7-fluoro-4H-benzo(1,4)oxazin-3-one
a(MESH:"4-(3-(4-butylpiperidin-1-yl)propyl)-7-fluoro-4H-benzo(1,4)oxazin-3-one") -> act(p(HGNC:CHRM1))
#77-LH-28-1 = 1-(3-(4-butyl-1-piperidinyl)propyl)-3,4-dihydro-2(1H)-quinolinone
a(MESH:"1-(3-(4-butyl-1-piperidinyl)propyl)-3,4-dihydro-2(1H)-quinolinone") -> act(p(HGNC:CHRM1))
act(p(HGNC:CHRM1)) -> bp(GO:cognition)

SET Evidence="Another early allosteric agonist, TBPB (1-(1’-(2-methylbenzyl)
-1,4’-bipiperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-1), also exhibited
impressive selectivity for M1 mAChRs and potentiated NMDA receptor currents
in CA1 hippocampal cells. "

SET MeSHAnatomy="CA1 Region, Hippocampal"

a(MESH:"1-(1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl)-1H-benzo(d)imidazol-2-(3H)-one") -> act(p(HGNC:CHRM1))
act(p(HGNC:CHRM1)) -> act(p(HGNCGENEFAMILY:"Glutamate ionotropic receptor NMDA type subunits"))

UNSET MeSHAnatomy

SET Evidence="Moreover, additional pre-clinical studies with TBPB
demonstrated efficacy in reducing antipsychotic-like behaviors and
in reversing scopolamine-impaired acquisition of contextual fear.59
Studies in cell lines also demonstrated that TBPB promoted a non-amyloidogenic
pathway and decreased Abeta production, indicating that M1 modulation may
have efficacy in the treatment of both symptomatic and pathologic features of AD"

a(MESH:"1-(1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl)-1H-benzo(d)imidazol-2-(3H)-one") -| act(a(CHEBI:scopolamine))
act(a(CHEBI:scopolamine)) -| bp(GO:"behavioral fear response")
a(MESH:"1-(1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl)-1H-benzo(d)imidazol-2-(3H)-one") -| a(CHEBI:"amyloid-beta")

SET Evidence="More recently, the M1-selective allosteric agonist VU0357017
was discovered, which displayed improved potency via binding to a
novel allosteric site on the M1 mAChR. VU0357017 significantly blocked
scopolamine-impaired contextual fear conditioning and enhanced spatial
and contextual fear learning"

a(MESH:VU0357017) -> complex(a(MESH:VU0357017), p(HGNC:CHRM1))
complex(a(MESH:VU0357017), p(HGNC:CHRM1)) -> act(p(HGNC:CHRM1))
a(MESH:VU0357017) -| act(a(CHEBI:scopolamine))
a(MESH:VU0357017) -> bp(GO:"behavioral fear response")

SET Evidence="A recent clinical study utilizing the M1-selective
allosteric agonist GSK1034702 demonstrated pro-cognitive efficacy
in a nicotine abstinence model of episodic memory impairment in smokers,
67 providing exciting evidence that M1-selective activation can provide
pro-cognitive benefits in humans"

complex(a(MESH:"GSK 1034702"), p(HGNC:CHRM1)) -> bp(GO:cognition)

SET Evidence="The first subtype-selective M1 PAM to be characterized
was benzyl quinolone carboxylic acid (BQCA);68 BQCA exhibited high
selectivity with no activity at mAChR subtypes M2–M5 and induced up
to a 129-fold leftward shift in ACh potency at the M1 mAChR"

#BQCA = 1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

a(MESH:"1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid") -> act(p(HGNC:CHRM1))
act(p(HGNC:CHRM1)) -> a(CHEBI:acetylcholine)

SET Evidence="In brain slice electrophysiology studies, BQCA
enhanced excitatory postsynaptic currents in medial prefrontal
cortical neurons,69 an area critical for higher cognitive, learning,
and memory functions.70 In pre-clinical animal studies, BQCA reversed
scopolamine-impaired contextual fear conditioning and rescued medial
prefrontal cortex-dependent discrimination reversal learning deficits
in a transgenic mouse model of AD."

SET MeSHAnatomy="Prefrontal Cortex"

a(MESH:"1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid") -> bp(GO:"excitatory postsynaptic potential")
a(MESH:"Prefrontal Cortex") -- bp(GO:cognition)
a(MESH:"Prefrontal Cortex") -- bp(GO:learning)
a(MESH:"Prefrontal Cortex") -- bp(GO:memory)

UNSET MeSHAnatomy

SET Species="10090"

a(MESH:"1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid") -| act(a(CHEBI:scopolamine))
a(MESH:"1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid") -> bp(GO:"behavioral fear response")
a(MESH:"1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid") -> bp(GO:learning)

UNSET Species

SET Evidence="Additionally, recent studies demonstrated that BQCA was
effective in reversing memory deficits in Y-maze object recognition
and spontaneous alternation tasks in rats.71,72"

SET Species="10116"

a(MESH:"1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid") -> bp(GO:memory)

UNSET Species

SET Evidence="Recent drug discovery efforts in our group have yielded
novel M1-selective PAMs VU0405652 (ML169) and VU0456940, both of
which potentiate M1-mediated non-amyloidogenic amyloid precursor
protein (APPsalpha) processing, suggesting disease-modifying potential in AD"

a(MESH:"VU 0405652") -> act(p(HGNC:CHRM1))
a(HBP:VU0456940) -> act(p(HGNC:CHRM1))
act(p(HGNC:CHRM1)) -> deg(a(HBP:"sAPP-alpha"))

SET Evidence="Conversely, the nonselective mAChR agonist BuTAC
([5R-(exo)]-6-[4-butylthio-1,2,5-thiadiazol-3-yl]-1-azabicyclo-[3.2.1]-octane)
shows an antipsychotic profile when tested in numerous preclinical animal
models. Administration of BuTAC reduces apomorphine-induced climbing and
apomorphine-induced disruptions of prepulse inhibition78,79 and reduces
conditioned avoidance responding in wild-type, but not M4 KO mice."

a(MESH:"6-(4-butylthio-1,2,5-thiadiazol-3-yl)-1-azabicyclo(3.2.1)octane") -| act(a(CHEBI:apomorphine))
act(a(CHEBI:apomorphine)) -| bp(GO:"prepulse inhibition")
a(MESH:"6-(4-butylthio-1,2,5-thiadiazol-3-yl)-1-azabicyclo(3.2.1)octane") -| path(MESH:"Avoidance Learning")
path(MESH:"Avoidance Learning") -- p(HGNC:CHRM4)

SET Evidence="The M4 receptor is highly expressed in the striatum,
hippocampus, and neocortex,45,46 suggesting that this mAChR subtype is
ideally located to modulate dopaminergic signaling. In support of this
hypothesis, M4 KO mice exhibit a hyperdopaminergic phenotype that is
resistant to mAChR agonist-induced attenuation of dopamine levels."

a(MESH:Hippocampus) -- p(HGNC:CHRM4)
a(MESH:"Corpus Striatum") -- p(HGNC:CHRM4)
a(MESH:Neocortex) -- p(HGNC:CHRM4)
p(HGNC:CHRM4) reg bp(GO:"synaptic transmission, dopaminergic")

SET Evidence="Two novel M4-selective compounds, VU10010 and LY2033298,
represented a breakthrough when they were described in 2008.84,85 VU10010
is a potent M4-selective PAM that increases affinity/efficacy of ACh to
promote M4 mAChR activation."

a(HBP:VU10010) -> act(a(CHEBI:acetylcholine))
act(a(CHEBI:acetylcholine)) -> act(p(HGNC:CHRM1))

SET Evidence="In brain slices, VU10010 selectively potentiated mAChR-mediated
reductions in glutamatergic, but not GABAergic, signaling in hippocampal
neurons, indicating a key role for M4 in regulating hippocampal function,
and possibly in modulating cognition."

SET MeSHAnatomy="Hippocampus"

a(HBP:VU10010) -> act(p(HGNC:CHRM4))
act(p(HGNC:CHRM4)) -| bp(GO:"synaptic transmission, glutamatergic")

UNSET MeSHAnatomy

SET Evidence="Both VU0152100 and VU0152099 effectively reversed
amphetamine-induced hyperlocomotion, demonstrating antipsychotic-like activity
in preclinical models."

a(MESH:"3-amino-N-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide")
a(HBP:VU0152099) -| act(a(CHEBI:amphetamine))
act(a(CHEBI:amphetamine)) -> bp(GO:locomotion)

SET Evidence="LY2033298, a structurally distinct M4-selective PAM, was
similarly efficacious in several preclinical models of psychosis, including
conditioned avoidance responding and apomorphine-impaired prepulse inhibition"

a(MESH:"3-amino-5-chloro-6-methoxy-4-methyl-thieno(2,3-b)pyridine-2-carboxylic acid cyclopropylamide") -| act(a(CHEBI:amphetamine))
act(a(CHEBI:apomorphine)) -| bp(GO:"prepulse inhibition")
